In a recent study by Cloughesy et al. investigating neoadjuvant and adjuvant anti-PD-1 therapy in patients with GBM, neoadjuvant treatment was found to activate T cells and IFN-γ response within the TME [163]. This evidence concerns the gene PDCD1 and glioblastoma.